期刊论文详细信息
Frontiers in Psychology | |
Is the serotonin hypothesis dead? If so, how will clinical psychology respond? | |
article | |
Nicholas C. Borgogna1  Stephen L. Aita2  | |
[1]Department of Psychological Sciences, Texas Tech University | |
[2]Veterans Affairs Maine Healthcare System | |
关键词: serotonin hypothesis; Affective Disorders; Depression; clinical psychologists; medication; | |
DOI : 10.3389/fpsyg.2022.1027375 | |
学科分类:社会科学、人文和艺术(综合) | |
来源: Frontiers | |
【 摘 要 】
For decades models of mental illness, particularly depression, have been influenced by the serotonin hypothesis (Coppen, 1967; Fakhoury, 2016). Specifically, that dysregulation in the serotonin neural system is an underlying biological cause of affective disorders. This model is the primary justification for the prescription of selective serotonin reuptake inhibitors (SSRIs; e.g., Prozac [Fluoxetine], Zoloft [Sertraline], Lexapro [Escitalopram]). SSRI prescription is extremely popular within modern psychiatry, with an estimated 13% of people living in the United States having taken an SSRI within the past 30 days (Brody and Gu, 2020). World-wide estimates are difficult to obtain, but developed European nations report commensurate prescribing activity (Abbing-Karahagopian et al., 2014), with indicators suggesting that SSRI prescriptions are increasing worldwide (Lockhart and Guthrie, 2011; Chen et al., 2022). Notably, estimates suggest the SSRI industry to be worth over $15 billion (USD) as of 2021 (Antidepressants Global Market Report 2021: COVID-19 Implications Growth to 2030, 2021).【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202307160005736ZK.pdf | 124KB | download |